Vagus Nerve Stimulation (VNS) in Refractory Epilepsy

Definition And Patient Selection

VNS is an invasive, adjunctive neuromodulatory therapy utilizing an implanted pulse generator to chronically stimulate the left vagus nerve.
Indicated for pediatric Drug-Resistant Epilepsy (DRE), defined as the failure of two or more appropriately chosen, optimally dosed anti-seizure medications (ASMs) to achieve sustained seizure freedom.
Target cohort includes patients unsuited for resective epilepsy surgery due to multifocal, generalized, or eloquent-cortex-involved epileptogenic zones.
Recent expansions include global regulatory approvals for children as young as 4 years, and off-label efficacy in Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC), and pediatric Refractory Status Epilepticus (RSE).

The left vagus nerve is strictly selected for implantation because the right vagus heavily innervates the cardiac sinoatrial (SA) node, posing an unacceptable risk of profound bradycardia or asystole.
Approximately 80% of vagal fibers are sensory afferents, projecting directly to the Nucleus Tractus Solitarius (NTS) in the medulla.
Signals relay from the NTS to the locus coeruleus and dorsal raphe nucleus, stimulating the widespread cortical release of inhibitory neurotransmitters, specifically norepinephrine, serotonin, and Gamma-Aminobutyric Acid (GABA).
This process alters resting-state networks, inducing thalamocortical desynchronization that raises the seizure threshold and actively prevents hypersynchronous ictal propagation.

The system comprises a titanium Implantable Pulse Generator (IPG) placed in a left infraclavicular pocket, connected to bipolar helical electrodes wrapped around the left cervical vagus nerve trunk.

Stimulation Mode	Mechanism And Clinical Application
Normal Mode	Delivers chronic, intermittent background stimulation (e.g., 30 seconds ON, 5 minutes OFF) for baseline prophylaxis, utilizing a gradually titrated output current.
Magnet Mode	On-demand, manual activation by caregivers swiping a specialized magnet over the IPG during an aura or witnessed seizure to abort or attenuate the event.
AutoStim Mode	Advanced closed-loop technology that detects sudden non-exertional ictal tachycardia (which precedes up to 82% of seizures) and automatically delivers a preemptive stimulation burst.

Complete seizure freedom is rare (under 10%), but 40% to 60% of pediatric patients achieve a responder rate of at least 50% reduction in total seizure frequency.
Efficacy is cumulative, with seizure control progressively improving over the first 12 to 24 months of continuous therapy.
VNS provides massive, independent neurobehavioral benefits, significantly improving alertness, mood, post-ictal recovery, and verbal communication.
Long-term VNS therapy is associated with a significantly reduced incidence of Sudden Unexpected Death in Epilepsy (SUDEP), potentially due to the cardioprotective effects of AutoStim addressing ictal autonomic dysregulation.

Systemic pharmacological side effects (cognitive dulling, hepatotoxicity, bone marrow suppression) are entirely absent.
Side effects are transient, occurring exclusively during the active "ON" stimulation phase due to co-stimulation of adjacent laryngeal and pharyngeal nerves.
Voice alteration or hoarseness is the most common side effect (up to 30%), alongside cough, throat paresthesia, and mild dyspnea upon exertion.
Surgical complications include hardware infection (3% to 6%), lead fracture, or lead migration.
VNS can exacerbate pre-existing sleep-disordered breathing and obstructive sleep apnea (OSA) by increasing upper airway resistance during stimulation cycles.